GT Biopharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference in September September 8, 2022
GT Biopharma Reports Second Quarter Fiscal 2022 Financial Results and Business Update August 11, 2022
GT Biopharma Presents Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager (TriKE®) Driving Robust NK Cell Function Against B Cell Malignancies at EHA 2022 Congress June 10, 2022
GT Biopharma Presents Preclinical Data Demonstrating Novel B7H3+ Tumor Targeting GTB-5550 TriKE® Driving NK Cell Activation and ADCC Against Head and Neck Squamous Cell Carcinomas at AACR Annual Meeting 2022 April 11, 2022
GT Biopharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update March 28, 2022
GT Biopharma Presents TriKE® Nanobody Pipeline (GTB-5550) Preclinical Multiple Myeloma Proof-of-Concept Data at 2022 EBMT Annual Meeting March 21, 2022
GT Biopharma Presented Preclinical Data Demonstrating Novel Mesothelin-Targeted TriKE® Driving Cytotoxicity Across All Stages of Non-Small Cell Lung Cancer at ESMO TAT 2022 March 9, 2022
